INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
Corporate insider
XC

Xu Cong Claire

SVP, Clinical DevelopmentCIK 0002114309

EDGAR filingsOpen in network
Disclosed transactions9
Buys / sells0 / 3
Max Insider Score22
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
XC
Xu Cong ClaireEVP, Clinical Development
NBPNovaBridge Biosciences
Option exercise
M—
4,079 sh
Aug 30, 2026Sep 1, 2026
traded Aug 30, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    NovaBridge BiosciencesSVP, Clinical Development · Jun 2, 2026
5
XC
Xu Cong ClaireEVP, Clinical Development
NBPNovaBridge Biosciences
Option exercise
M
—
9,382 sh
Aug 30, 2026
Sep 1, 2026
traded Aug 30, 2026
+2d
SEC FORM 4

Evidence

22
XC
Xu Cong ClaireEVP, Clinical Development
NBPNovaBridge Biosciences
Open-market sale
SELL$2,593
3,282 sh
Aug 31, 2026Sep 1, 2026
traded Aug 31, 2026
+1dSEC FORM 4

Evidence

17
XC
Xu Cong ClaireSVP, Clinical Development
NBPNovaBridge Biosciences
Open-market sale
SELL$3,992
4,485 sh
Jul 6, 2026Jul 7, 2026
traded Jul 6, 2026
+1dSEC FORM 4

Evidence

5
XC
Xu Cong ClaireSVP, Clinical Development
NBPNovaBridge Biosciences
Option exercise
M—
5,405 sh
Jul 4, 2026Jul 7, 2026
traded Jul 4, 2026
+3dSEC FORM 4

Evidence

5
XC
Xu Cong ClaireSVP, Clinical Development
NBPNovaBridge Biosciences
Option exercise
M—
12.4K sh
Jul 4, 2026Jul 7, 2026
traded Jul 4, 2026
+3dSEC FORM 4

Evidence

13
XC
Xu Cong ClaireSVP, Clinical Development
NBPNovaBridge Biosciences
Option exercise
M—
4,079 sh
May 30, 2026Jun 2, 2026
traded May 30, 2026
+3dSEC FORM 4

Evidence

9
XC
Xu Cong ClaireSVP, Clinical Development
NBPNovaBridge Biosciences
Option exercise
M—
9,382 sh
May 30, 2026Jun 2, 2026
traded May 30, 2026
+3dSEC FORM 4

Evidence

21
XC
Xu Cong ClaireSVP, Clinical Development
NBPNovaBridge Biosciences
Open-market sale
SELL$14K
3,494 sh
Jun 1, 2026Jun 2, 2026
traded Jun 1, 2026
+1dSEC FORM 4

Evidence